Pyxis Oncology surges 16% on 39% response rate in MICVO Phase I update

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Pyxis Oncology (PYXS.US) surged more than 16% during regular trading to $1.64.

The company reported updated Phase I trial results for MICVO in previously treated patients with recurrent or metastatic head and neck cancer, showing a confirmed response rate of 39%, median progression-free survival of 6.7 months and median duration of response of 9.2 months among 33 second-line or later patients.

Pyxis Oncology said clinical activity was consistent across patient subgroups with a manageable safety profile, noting the data may support its planned mid-2027 launch of the global Phase III Headliner trial.

Separately, the company narrowed its third-quarter net loss to $19.98 million. Previously disclosed MICVO monotherapy data in advanced head and neck cancer showed a confirmed response rate of 36% and median progression-free survival of 6.2 months.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.